MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Roivant Sciences Ltd

Cerrado

SectorSanidad

11.42 -1.89

Resumen

Variación precio

24h

Actual

Mínimo

11.38

Máximo

11.7

Métricas clave

By Trading Economics

Ingresos

-278M

-252M

Ventas

-1.4M

7.6M

BPA

-0.29

Margen de beneficios

-3,333.884

Empleados

750

EBITDA

-9.2M

-284M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+38.65% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

313M

7.9B

Apertura anterior

13.31

Cierre anterior

11.42

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

169 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Roivant Sciences Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 jul 2025, 23:34 UTC

Adquisiciones, fusiones, absorciones

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 jul 2025, 21:14 UTC

Adquisiciones, fusiones, absorciones

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 jul 2025, 21:04 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 jul 2025, 23:43 UTC

Charlas de Mercado

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 jul 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 jul 2025, 22:47 UTC

Adquisiciones, fusiones, absorciones

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 jul 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 jul 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 jul 2025, 22:43 UTC

Adquisiciones, fusiones, absorciones

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 jul 2025, 22:43 UTC

Adquisiciones, fusiones, absorciones

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 jul 2025, 22:40 UTC

Adquisiciones, fusiones, absorciones

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 jul 2025, 22:40 UTC

Adquisiciones, fusiones, absorciones

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 jul 2025, 22:30 UTC

Charlas de Mercado
Ganancias

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 jul 2025, 22:20 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

17 jul 2025, 22:20 UTC

Charlas de Mercado
Ganancias

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 jul 2025, 22:04 UTC

Charlas de Mercado
Ganancias

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 jul 2025, 22:03 UTC

Adquisiciones, fusiones, absorciones

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 jul 2025, 21:58 UTC

Charlas de Mercado
Ganancias

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 jul 2025, 21:57 UTC

Ganancias

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 jul 2025, 21:47 UTC

Ganancias

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 jul 2025, 21:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 jul 2025, 21:45 UTC

Charlas de Mercado

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 jul 2025, 21:38 UTC

Adquisiciones, fusiones, absorciones

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 jul 2025, 21:22 UTC

Adquisiciones, fusiones, absorciones

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 jul 2025, 21:05 UTC

Ganancias

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 jul 2025, 21:04 UTC

Adquisiciones, fusiones, absorciones

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 jul 2025, 21:02 UTC

Adquisiciones, fusiones, absorciones

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 jul 2025, 20:59 UTC

Adquisiciones, fusiones, absorciones

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 jul 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

17 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Roivant Sciences Ltd previsión

Precio Objetivo

By TipRanks

38.65% repunte

Estimación a 12 Meses

Media 16 USD  38.65%

Máximo 19 USD

Mínimo 12 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Roivant Sciences Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

7

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

11 / 11.18Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

169 / 376 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.